RESULTS Ovarian Preneoplasia and Neoplasia Induced in Rats with DMBA Female Sprague

Animal models of ovarian cancer are crucial for understanding the pathogenesis of the disease and for testing new treatment strategies. A model of ovarian carcinogenesis in the rat was modified and improved to yield ovarian preneoplastic and neoplastic lesions that pathogenetically resemble human ovarian cancer. A significantly lower dose (2 to 5 g per ovary) of 7,12-dimethylbenz(a)anthracene (DMBA) was applied to the one ovary to maximally preserve its structural integrity. DMBA-induced mutagenesis was additionally combined with repetitive gonadotropin hormone stimulation to induce multiple cycles of active proliferation of the ovarian surface epithelium. Animals were treated in three arms of different doses of DMBA alone or followed by hormone administration. Comparison of the DMBA-treated ovaries with the contralateral control organs revealed the presence of epithelial cell origin lesions at morphologically distinct stages of preneoplasia and neoplasia. Their histopathology and path of dissemination to other organs are very similar to human ovarian cancer. Hormone cotreatment led to an increased lesion severity, indicating that gonadotropins may promote ovarian cancer progression. Point mutations in the Tp53 and Ki-Ras genes were detected that are also characteristic of human ovarian carcinomas. Additionally, an overexpression of estrogen and progesterone receptors was observed in preneoplastic and early neoplastic lesions, suggesting a role of these receptors in ovarian cancer development. These data indicate that this DMBA animal model gives rise to ovarian lesions that closely resemble human ovarian cancer and it is adequate for additional studies on the mechanisms of the disease and its clinical management.

[1]  A. Børresen-Dale,et al.  TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival , 2004, British Journal of Cancer.

[2]  T. Querec,et al.  Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium , 2004, Journal of cellular physiology.

[3]  R. Ozols Atlas of Clinical Oncology , 2003 .

[4]  T. Page,et al.  7,12-Dimethylbenz[a]anthracene-induced bone marrow toxicity is p53-dependent. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  R. L. Baldwin,et al.  Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. , 2003, American journal of obstetrics and gynecology.

[6]  A. Flesken-Nikitin,et al.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.

[7]  B. Vanderhyden,et al.  Translational research in ovarian cancer: a must , 2003, International Journal of Gynecologic Cancer.

[8]  K. Stakleff,et al.  Rodent models for ovarian cancer research , 2003, International Journal of Gynecologic Cancer.

[9]  Barbara C Vanderhyden,et al.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. , 2003, Cancer research.

[10]  T. Page,et al.  7,12-Dimethylbenz[a]anthracene induces apoptosis in murine pre-B cells through a caspase-8-dependent pathway. , 2002, Molecular pharmacology.

[11]  H. Varmus,et al.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. , 2002, Cancer cell.

[12]  G. Heinze,et al.  Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients , 2001, International journal of cancer.

[13]  A. Spurdle,et al.  No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. , 2001, Carcinogenesis.

[14]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[15]  K. Tsuta,et al.  Mechanisms of adrenal damage induced by 7,12-dimethylbenz (alpha) anthrancene in female Sprague--Dawley rats. , 2001, Experimental and molecular pathology.

[16]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[17]  D Lowe,et al.  Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Journal of the National Cancer Institute.

[18]  K. Ushijima,et al.  Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12‐dimethylbenz[a]anthracene‐coated suture , 1998, Cancer.

[19]  A. Berchuck,et al.  Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. , 1998, British Journal of Cancer.

[20]  R. Gupta,et al.  Tissue distribution of DNA adducts in rats treated by intramammillary injection with dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene. , 1997, Mutation research.

[21]  T. Koh,et al.  Loss of heterozygosity at the N‐ras locus in 7,12‐dimethylbenz[a]anthracene‐induced rat leukemia , 1997, Molecular carcinogenesis.

[22]  A. Godwin,et al.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.

[23]  Norifumi Ueda,et al.  Incidence of p53 and Ha‐ras gene mutations in chemically induced rat mammary carcinomas , 1996, Molecular carcinogenesis.

[24]  S. Chow,et al.  Point mutation of the ras oncogene in human ovarian cancer. , 1993, DNA and cell biology.

[25]  J. Prat,et al.  Morphologic Precursors of Ovarian Epithelial Tumors , 1993, Obstetrics and gynecology.

[26]  A. Thor,et al.  p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Inoue,et al.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. , 1991, The American journal of pathology.

[28]  G. Bryan,et al.  Chemical induction of ovarian tumors in rats. , 1985, Gynecologic oncology.

[29]  H. Gralnick,et al.  A VARIANT FORM OF HYPERGRANULAR PROMYELOCYTIC LEUKAEMIA (M3) , 1980, British journal of haematology.

[30]  S. Sekiya,et al.  In vivo and in vitro studies of experimental ovarian adenocarcinoma in rats. , 1979, Cancer research.

[31]  M. Yakushiji,et al.  [Experimental ovarian tumor. 1. Experimental ovarian tumor producced in rats by a chemical carcinogen, 20-methylcholanthrene]. , 1973, Igaku kenkyu. Acta medica.

[32]  M. Fathalla Factors in the causation and incidence of ovarian cancer. , 1972, Obstetrical & gynecological survey.

[33]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.

[34]  E. Wynder,et al.  Epidemiology of cancer of the ovary , 1969, Cancer.

[35]  R. Ozols,et al.  Focus on epithelial ovarian cancer. , 2004, Cancer cell.

[36]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  I. Ember,et al.  Effect of 7,12-dimethylbenz(a)anthracene on onco/suppressor gene action in vivo: a short-term experiment. , 1998, Anticancer research.

[38]  T. Koh,et al.  The specific N-ras mutation in rat 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. , 1997, Leukemia.

[39]  R. Scully Pathology of ovarian cancer precursors , 1995, Journal of cellular biochemistry. Supplement.

[40]  M. Kogevinas,et al.  Identification of occupational carcinogens. , 1994, IARC scientific publications.

[41]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[42]  D. Mattison,et al.  Morphometric assessment of the murine ovarian toxicity of 7,12-dimethylbenz(a)anthracene. , 1992, Reproductive toxicology.

[43]  P. Russell The pathological assessment of ovarian neoplasms. III: The malignant "epithelial" tumours. , 1979, Pathology.

[44]  K. L. Duke,et al.  Comparative morphology of the mammalian ovary , 1973 .